Author

Vivian Ng

Observed names: Ng, Vivian, V. Ng, Vivian W. Ng

Institution: Genentech

Observed institutions: Semmelweis University, Roche (United States), University of California, Los Angeles, Genentech, Fondazione IRCCS Istituto Nazionale dei Tumori, UCLA Jonsson Comprehensive Cancer Center, Stony Brook University

OpenAlex ID: A5111725395

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

2014 · Eric Van Cutsem, Yung-Jue Bang, et al. · Gastric Cancer · 609

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

2013 · Sara A. Hurvitz, Luc Dirix, et al. · Journal of Clinical Oncology · 392

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

2014 · Valérie F. Cosson, Vivian W. Ng, et al. · Cancer Chemotherapy and Pharmacology · 107

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

2018 · Patrick Schöffski, Sara Cresta, et al. · Breast Cancer Research · 92

Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results

2015 · Ian Krop, Stephen Johnston, et al. · Cancer Research · 60

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

2014 · Edith A Perez, Sara A Hurvitz, et al. · Breast Cancer Research · 58

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.

2016 · Jose Baselga, Javier Cortes, et al. · Journal of Clinical Oncology · 18

LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.

2016 · Cristina Saura, Evandro De Azambuja, et al. · Journal of Clinical Oncology · 4

Exploratory Analysis of the Relationship Between Her2 Expression (BY QRT-PCR) and Efficacy with First-Line Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (HT) in a Randomized Phase 2 Study of Patients (PTS) with HER2-Positive MBC

2012 · E.A. Perez, S. Hurvitz, et al. · Annals of Oncology · 2

Works count: 13

Citation count: 1,342

H-index: 7

I10-index: 7